February 23, 2024

Watch: Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences (Webinar Recording)

Wave Life Sciences recently joined PPMD for a community webinar to share an update on the company’s FORWARD-53 study. Wave provided an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular…

Learn More

December 15, 2023

Wave Life Sciences Announces Initiation of Dosing in Phase 2 Duchenne Clinical Trial of WVE-N531

Wave Life Sciences recently shared that the company has initiated dosing and has fully enrolled the Phase 2 FORWARD-53 trial of investigational WVE-N531, a potential exon skipping therapy targeting people with Duchenne amenable to exon…

Learn More

September 29, 2021

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Duchenne Clinical Trial of WVE-N531 Starting in Canada and the UK

  This morning, Wave Life Sciences Ltd. announced the initiation of dosing in a Phase 1b/2a clinical trial expecting to enroll 15 boys, evaluating investigational WVE-N531 as a treatment for boys with Duchenne muscular dystrophy…

Learn More

January 15, 2020

WATCH: Update on Investigational Suvodirsen in Duchenne Muscular Dystrophy – Webinar Recording

On December 20, 2019, Parent Project Muscular Dystrophy (PPMD) and World Duchenne Organization (WDO) hosted an informational webinar with the Wave Life Sciences team to discuss their decision to discontinue development of suvodirsen for patients…

Learn More

December 16, 2019

Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne

Wave Life Sciences Ltd. announced its decision to discontinue development of suvodirsen for patients with Duchenne who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension…

Learn More

November 4, 2019

End Duchenne Tour Recap: Memphis, TN

PPMD’s End Duchenne Tour made a stop in Memphis, TN on Saturday, October 26. We were joined by over 60 people,  including families, an amazing group of volunteers in our kids room, six members of…

Learn More

October 22, 2019

WATCH: DYSTANCE 51, a Phase 2/3 Clinical Trial of Investigational Suvodirsen – Webinar Recording

Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave Life Sciences is a clinical-stage…

Learn More

October 7, 2019

2019 World Muscle Society Update – Days 2 & 3

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

September 24, 2019

End Duchenne Tour Recap: Wilmington, Delaware

PPMD’s End Duchenne Tour made a stop in Wilmington, Delaware on September 14. We were joined by over 100 people, including 30 families, 20 healthcare professionals and researchers, 15 industry partners, and 5 members of…

Learn More

September 16, 2019

Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

Wave Life Sciences shared today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to suvodirsen for the treatment of Duchenne in patients amenable to exon 51 skipping. Fast Track designation…

Learn More